• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Abuse Deterrent Formulation Science Meeting

A discussion about the Food and Drug Administration’s draft guidance for industry: “Abuse Deterrent Opioids – Evaluation and Labeling,” will be heldSeptember 30-October 1, 2013. The discussion is part of the Abuse Deterrent Formulation Science meeting, being held at the Bethesda North Marriott Conference Center, in Bethesda, Md.

The meeting is organized by the Cross-Company Abuse Liability Consortium and facilitated with the aid of the College on Problems of Drug Dependence. The Safety Pharmacology Society is also sponsoring the meeting. The meeting is being convened to provide an open forum to foster discussion and recommendations about the draft guidance.

Presentations will be given by an international group of academicians, industry representatives, and FDA staff. In addition to formal presentations, several panels will discuss the following topics from draft guidance: laboratory manipulation and extraction studies; pharmacokinetic and clinical abuse potential studies; and postmarketing studies and drug labeling.

The registration fee is $500.

See link below for more information: http://adfsciencemeeting.com/